A detailed history of Daiwa Securities Group Inc. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 15,868 shares of AUTL stock, worth $57,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,868
Previous 575 2659.65%
Holding current value
$57,600
Previous $4,000 1275.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$3.33 - $5.68 $50,925 - $86,864
15,293 Added 2659.65%
15,868 $55,000
Q4 2023

Jan 31, 2024

BUY
$2.13 - $6.63 $1,224 - $3,812
575 New
575 $4,000
Q4 2020

Feb 04, 2021

SELL
$8.13 - $12.79 $764 - $1,202
-94 Reduced 55.95%
74 $1,000
Q3 2019

Nov 04, 2019

BUY
$9.79 - $16.72 $518 - $886
53 Added 46.09%
168 $2,000
Q1 2019

Apr 26, 2019

SELL
$24.38 - $34.71 $2,072 - $2,950
-85 Reduced 42.5%
115 $4,000
Q4 2018

Feb 05, 2019

BUY
$24.21 - $48.01 $4,842 - $9,602
200 New
200 $7,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $330M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.